Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10328059" target="_blank" >RIV/00064165:_____/16:10328059 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10328059

Result on the web

<a href="http://dx.doi.org/10.1212/NXI.0000000000000194" target="_blank" >http://dx.doi.org/10.1212/NXI.0000000000000194</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/NXI.0000000000000194" target="_blank" >10.1212/NXI.0000000000000194</a>

Result language

angličtina

Original language name

Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months

Original language description

Objective: To analyze changes in T-helper (Th) subsets, T-regulatory (Treg) cell percentages and function, and mRNA levels of immunologically relevant molecules during a 24-month follow-up after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Multicenter follow-up of 29 alemtuzumab-treated patients with RRMS in the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I and CARE-MS II trials. Peripheral blood (PB) samples were obtained at months 0, 6, 12, 18, and 24. We evaluated (1) mRNA levels of 26 immunologic molecules (cytokines, chemokines, chemokine receptors, and transcriptional factors); (2) Th1, Th17, and Treg cell percentages; and (3) myelin basic protein (MBP)-specific Treg suppressor activity. Results: We observed 12 relapses in 9 patients. mRNA levels of the anti-inflammatory cytokines interleukin (IL)-10, IL-27, and transforming growth factor-beta persistently increased whereas those of proinflammatory molecules related to the Th1 or Th17 subsets persistently decreased after alemtuzumab administration throughout the follow-up period. PB CD4+ cell percentage remained significantly lower than baseline while that of Th1 and Th17 cells did not significantly change. A significant increase in Treg cell percentage was observed at month 24 and was accompanied by an increase in Treg cell suppressive activity against MBP-specific Th1 and Th17 cells. Conclusions: The long-lasting therapeutic benefit of alemtuzumab in RRMS may involve a shift in the cytokine balance towards inhibition of inflammation associated with a reconstitution of the PB CD41 T-cell subsets that includes expansion of Treg cells with increased suppressive function. Neurol Neuroimmunol Neuroinflamm 2016;3:e194; doi: 10.1212/NXI.0000000000000194

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neurology: Neuroimmunology &amp; Neuroinflammation [online]

ISSN

2332-7812

e-ISSN

—

Volume of the periodical

3

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

—

UT code for WoS article

000384572500012

EID of the result in the Scopus database

—